

SUPPLEMENTARY TABLES

Supplementary Table 1. Definition of liver steatosis and fibrosis biomarkers and relative cutoffs

Liver steatosis		
Biomarker	Algorithm	Cut-offs
Fatty Liver Index (FLI)	$e^y / (1 + e^y) \times 100$ Where $y = 0.953 \times \ln(\text{triglycerides, mg/dL}) + 0.139 \times \text{BMI, kg/m}^2 + 0.718 \times \ln(\text{GGT, U/L}) + 0.053 \times \text{waist circumference, cm} - 15.745$	30 and 60
Hepatic Steatosis Index (HSI)	$\text{HSI} = 8 \times \text{ALT/AST} + \text{BMI} (+ 2 \text{ if type 2 diabetes yes, } + 2 \text{ if female})$	30 and 36
NAFLD Ridge Score (NRS)	$-0.614 + 0.007 \times \text{ALT} - 0.214 \times \text{HDL-C} + 0.053 \times \text{triglyceride} + 0.144 \times \text{HbA1c} + 0.032 \times \text{WBC} + 0.132 \times \text{HT}$	0.24 and 0.44
Liver fibrosis		
Biomarker	Algorithm	Cut-offs
NAFLD Fibrosis Score (NFS)	$-1.675 + (0.037 \times \text{age [years]}) + (0.094 \times \text{BMI [kg/m}^2\text{]}) + (1.13 \times \text{IFG/diabetes [yes = 1, no = 0]}) + (0.99 \times \text{AST/ALT ratio}) - (0.013 \times \text{platelet count [} \times 10^9\text{/L]}) - (0.66 \times \text{albumin [g/dl]})$	-1.455 and 0.675
Fibrosis-4 (FIB-4)	$(\text{age (years)} \times \text{AST (IU/L)}) / (\text{platelet count (} 10^9\text{/L)} \times \text{ALT (IU/L)})$	1.3 and 2.67
AST/ALT	$\text{AST (IU/L)} / \text{ALT (IU/L)}$	0.8 and 1.4
AST to platelet ratio index (APRI)	$(\text{AST (IU/L)} / \text{AST (ULN)}) / \text{platelet count (} 10^9\text{/L)} \times 100$	0.5 and 1.5

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma glutamyltransferase; ULN, upper limit of normal; WBC, white blood cells; HT, hypertension

9 **Supplementary Table 2.** Anthropometric and biochemical features of the study subjects

10

<i>Variables</i>	<i>ENTIRE POPULATION</i>	<i>FLI</i>	<i>HIS</i>	<i>NAFLD RIDGE SCORE</i>	<i>AST / ALT</i>	<i>APRI</i>	<i>FIB-4</i>	<i>NAFLD FIBROSIS SCORE</i>
Number (Male/Female)	2770 (1637/1133)	1519 (930/653)	2076 (1218/860)	1082 (663/449)	2096 (1223/873)	1429 (843/586)	1421 (837/584)	370 (229/141)
Age (yrs)	68 ± 12	67 ± 11	68 ± 12	68 ± 12	68 ± 12	68 ± 12	68 ± 12	69 ± 11
BMI (kg/m²)	30.23 ± 5.93	30.56 ± 6	30.32 ± 5.91	30.78 ± 6.06	30.32 ± 5.91	30.48 ± 6	30.47 ± 6.01	31.14 ± 6.6
Waist circumference (cm)	106 ± 14	106 ± 14	106 ± 14	107 ± 14	106 ± 14	106 ± 14	106 ± 14	108 ± 15
Systolic Blood Pressure (mmHg)	140 ± 42	140 ± 33	140 ± 39	140 ± 37	140 ± 39	139 ± 34	139 ± 34	141 ± 22
Diastolic Blood Pressure (mmHg)	78 ± 12	78 ± 12	78 ± 12	77 ± 12	78 ± 12	78 ± 12	78 ± 12	77 ± 13
Heart Rate (bpm)	78 ± 13	78 ± 13	78 ± 13	78 ± 13	78 ± 13	78 ± 14	78 ± 14	78 ± 13
T2DM duration (yrs)	10 ± 9	10 ± 9	9 ± 9	10 ± 9	9 ± 9	9 ± 9	10 ± 9	10 ± 9
Fasting plasma glucose (mg/dL)	150 ± 68	149 ± 72	149 ± 69	147 ± 61	149 ± 69	149 ± 63	149 ± 63	144 ± 48
HbA1c (%)	7.4 ± 3.9	7.2 ± 1.3	7.3 ± 1.4	7.2 ± 1.3	7.3 ± 1.4	7.3 ± 1.3	7.3 ± 1.3	7.1 ± 1.3
Creatinine (mg/dL)	1.05 ± 0.68	1.03 ± 0.65	1.03 ± 0.62	1.04 ± 0.63	1.03 ± 0.63	1.05 ± 0.67	1.05 ± 0.67	1.12 ± 0.84
eGFR EPI-CKD (mL/min/1.73 m²)	74.24 ± 24.33	75.76 ± 23.84	75.47 ± 23.87	74.86 ± 24.14	75.32 ± 23.95	74.84 ± 24.33	74.79 ± 24.33	72.66 ± 25.23
Uric acid (mg/dL)	5.6 ± 1.7	5.6 ± 1.7	5.6 ± 1.7	5.6 ± 1.6	5.6 ± 1.7	5.6 ± 1.6	5.6 ± 1.6	5.5 ± 1.6
Total cholesterol (mg/dL)	173 ± 46	172 ± 41	172 ± 40	169 ± 39	172 ± 40	170 ± 41	170 ± 40	168 ± 42
HDL cholesterol (mg/dL)	48 ± 14	48 ± 14	48 ± 14	48 ± 15	48 ± 14	48 ± 15	48 ± 14	48 ± 16
Triglycerides (mg/dL)	143 ± 88	144 ± 86	142 ± 83	143 ± 88	142 ± 83	143 ± 85	143 ± 85	146 ± 94
LDL cholesterol (mg/dL)	97 ± 40	96 ± 34	96 ± 34	94 ± 34	96 ± 34	94 ± 34	95 ± 34	92 ± 37
AST (U/L)	23 ± 17	22 ± 14	22 ± 16	21 ± 11	22 ± 16	22 ± 13	22 ± 13	22 ± 13
ALT (U/L)	27 ± 25	26 ± 20	26 ± 24	24 ± 15	26 ± 24	26 ± 20	26 ± 20	25 ± 21
GGT (U/L)	51 ± 80	47 ± 70	49 ± 78	45 ± 63	49 ± 78	50 ± 73	50 ± 73	55 ± 86
Platelet count (10 ⁹ /L)	238 ± 75	240 ± 76	238 ± 75	240 ± 74	239 ± 75	239 ± 75	239 ± 75	239 ± 77
TSH (mU/L)	2.44 ± 3.91	2.27 ± 1.94	2.24 ± 1.9	2.27 ± 1.84	2.24 ± 1.89	2.26 ± 1.87	2.26 ± 1.87	2.27 ± 2.01
Current smokers (%)	16.5%	17.4%	16.8%	16.1%	16.8%	15.9%	15.8%	15.5%

Metabolic syndrome (%)	90.6%	89.6%	90.1%	90.5%	90.1%	90.8%	90.9%	91.6%
Microalbuminuria (%)	29.3%	30.4%	29.3%	28.9%	29.5%	30.0%	29.9%	32.8%
Diabetic rethinopathy (%)	17.8%	17.9%	16.7%	17.7%	16.7%	16.8%	16.9%	20.5%
Cardiovascular event (%)	40.4%	40.7%	39.8%	44.6%	40.0%	42.9%	42.9%	53.8%
eGFR EPI-CKD ≤ 90	69.6%	67.0%	68.0%	67.5%	68.2%	68.7%	68.7%	71.0%
eGFR EPI-CKD ≤ 60	27.1%	25.1%	25.5%	27.1%	25.7%	26.5%	26.5%	29.3%
eGFR EPI-CKD ≤ 30	5.5%	4.5%	4.4%	4.8%	4.6%	5.1%	5.1%	6.1%
Oral antidiabetic therapy (%)	74.5%	76.8%	75.6%	77.1%	75.5%	75.3%	75.3%	73.8%
Therapy with insulin (%)	26.2%	27.6%	26.2%	29.2%	26.2%	27.7%	27.8%	32.2%
Therapy with statins (%)	57.5%	62.5%	60.1%	65.6%	60.1%	62.7%	62.8%	62.7%
Antihypertensive therapy (%)	75.5%	75.8%	75.3%	77.5%	75.5%	76.9%	76.9%	79.7%
ACE inhibitor therapy (%)	38.6%	39.4%	39.1%	40.4%	39.1%	40.2%	40.3%	38.1%
Angiotensin receptor blocker therapy (%)	22.8%	23.6%	23.1%	23.9%	23.1%	23.7%	23.7%	26.5%
Calcium channel blockers (%)	25.0%	25.4%	24.5%	26.2%	24.5%	26.0%	26.1%	28.9%
Diuretics (%)	39.9%	40.2%	39.2%	41.7%	39.4%	41.2%	41.2%	45.1%
□-Blockers therapy (%)	35.6%	35.9%	34.7%	37.5%	34.7%	37.4%	37.3%	40.5%
10 years CHD risk (%)	26.26 ± 16.70	26.03 ± 16.81	25.89 ± 16.56	25.96 ± 16.73	25.95 ± 16.62	26.4 ± 17.14	26.44 ± 17.14	27.51 ± 17.75
10 years fatal CHD risk (%)	20.45 ± 15.71	20.26 ± 15.83	20.07 ± 15.55	20.13 ± 15.74	20.13 ± 15.62	20.55 ± 16.12	20.58 ± 16.12	21.45 ± 16.5
10 years stroke risk (%)	22.31 ± 21.67	22.11 ± 21.83	21.85 ± 21.54	22.19 ± 21.99	21.9 ± 21.59	22.55 ± 22.08	22.59 ± 22.1	23.58 ± 21.97
10 years fatal stroke risk (%)	3.60 ± 4.87	3.65 ± 5.4	3.56 ± 5.04	3.57 ± 4.88	3.56 ± 5.04	3.66 ± 5.48	3.67 ± 5.48	3.66 ± 3.69

11

12 Values are presented as the mean ± standard deviation or percentage.

13 Abbreviations: HbA1c, hemoglobin A1C; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma

14 glutamyltransferase; TSH, Thyroid-stimulating hormone

15